

- modelling the extra-hepatic biooxidation of exogens. *Biochimica* 69: 3-9
- O'Brien, P. J. (1985) Free radical mediated DNA binding. *Environmental Health Perspectives* 64: 219-232
- O'Brien, P. J., Gregory, B., Fourney, B., Davison, W., Rahimula, A.D., Tsuruta, Y. (1985) One-electron oxidation in cell toxicity. In: Boobis, A. R., Caldwell, J., Matteis, F., Elcombe, C. R. (eds) *Microsomes and Drug Oxidations*, Ellis Horwood, London, pp 284-295
- Patterson, L. H., Gandecha, B. M., Brown, J. R. (1983) Ametantrone, an anthraquinone antitumour agent that does not cause lipid peroxidation in vivo. Comparison with daunorubicin. *Biochem. Biophys Res. Commun.* 110: 399-405
- Reszka, K., Kolodziejczyk, P., Lown, J. W. (1988) Enzymatic oxidative activation and transformation of the antitumour agent mitoxantrone. *J. Free Rad. Biol. Med.* 5: 13-2
- Reszka, K., Kolodziejczyk, P., Lown, J. W. (1989) Enzymatic oxidation of 5-iminodaunorubicin. Spectrophotometric and electron paramagnetic resonance studies. *Biochem. Pharmacol.* 38: 803-809
- Sinha, B.K., Motten, A.G., Hanck, K.W. (1983) The electrochemical reduction of mitoxantrone and daunomycin: biochemical significance in superoxide formation. *Chem.-Biol. Interact.* 43: 371-373
- Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., Lui, L.F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* 226: 466-468

*J. Pharm. Pharmacol.* 1991, 43: 68-69  
Communicated April 16, 1990

© 1991 *J. Pharm. Pharmacol.*

## New heteroaryl derivatives of fentanyl

E. F. LLAMA, C. DEL CAMPO, M. CAPO\*, *Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain*, \**Departamento de Farmacología, Facultad de Veterinaria, Universidad Complutense, 28040 Madrid, Spain*

**Abstract**—The preparation of analogues of fentanyl with *N*-phenyl replaced with a heterocyclic aromatic ring, and with *N*-alkyl/arylalkyl *N*-acyl substituents is reported. Only those compounds carrying an *N*-phenylethyl substituent were active in the rat tail-withdrawal test. Fentanyl (1) is the prototype of the 4-anilidopiperidine class of opioid analgesics (Casy & Parfitt 1986). Several recent publications (Casy & Huckstep 1988; Bagley et al 1989) on this series have dealt with heterocyclic and aromatic modifications of the fentanyl molecule. Although the antinociceptive potency of most novel derivatives was greater than that of morphine, they had reduced activity when compared with fentanyl itself. To acquire further information on the structure-reactivity relationships of the series, new heteroaryl derivatives have been prepared and tested for antinociceptive activity.

### Chemistry

The intermediate 4-(heteroanilido)-piperidines were obtained by treating the 4-amino-*N*-substituted piperidine with the appropriate heterocyclic halide. Acylation of these products with the corresponding acid chloride in the presence of triethylamine (Lobezoo et al 1980) yielded the required fentanyl analogues 2-13 (Table 1). Infra-red spectroscopy, <sup>1</sup>H-NMR spectroscopy and elemental analysis confirmed the structures shown.

### Preparative work

Melting points are uncorrected. Spectroscopic data (IR, <sup>1</sup>H-NMR) support structures in all cases. Microanalyses were performed on a Perkin-Elmer 240 by CSIC laboratories (Madrid Spain).

5-Bromo and 8-bromoquinolines were prepared as described by Butler & Gordon (1975), 5-bromoisoquinoline as described by Gordon & Pearson (1964), 9-chloroacridine as described by Atwell et al (1984), and 7-chlorobenzo[b][1,8]phenanthroline as described by Elslager & Tendrick (1962). 1-Methyl-4-aminopiperidine and 1-phenylethyl-4-aminopiperidine were prepared

by reduction of the corresponding 4-piperidone oximes with lithium aluminium hydride by the standard procedure (Harper & Chignell 1964).

**4-Heteroanilido-piperidines (general procedure).** A mixture of 4-aminopiperidine-*N*-substituted (40 mmol), heteroaryl halide (20 mmol), copper powder (20 mmol) and triethylamine (5 mL) in 1-pentanol (30 mL) was stirred at the reflux temperature for 4 h. The mixture was concentrated in-vacuo and the solid was added to 10% HCl (50 mL). The suspension was stirred and the melt was poured slowly into an excess of ice and concentrated ammonium hydroxide (150 mL) and extracted with ether (4 × 100 mL). The organic layer was washed with water and dried over anhydrous sodium sulphate. The crude products were purified by column chromatography and recrystallized.

**4-Heteroanilido-4-acyl-piperidines (2-13) (general procedure).** To a mixture of 4-heteroanilidopiperidine (20 mmol) in chloroform (30 mL) and triethylamine (5 mL) was added dropwise a solution of the acid chloride (30 mL) in chloroform (5 mL). The reaction mixture was stirred at reflux temperature for 1 h. The mixture was concentrated in-vacuo and the residue was extracted with 10% HCl-ether (1:1) (50 mL). The aqueous layer was alkalinized with concentrated ammonium hydroxide (100 mL) and extracted with chloroform (4 × 100 mL), washed with water and dried over anhydrous sodium sulphate. The products were purified by recrystallization.

### Pharmacology and discussion

The antinociceptive activities of fentanyl and its analogues were assessed in rats by the tail-withdrawal test (Janssen et al 1963, Table 1). When the *N*-phenylethyl and *N*-propionyl substituents were present (compounds 2-5), the antinociceptive activity decreased while a complete lack of activity at 2.5 mg kg<sup>-1</sup> was observed for compound 6 with an increased steric bulk (Series 5A). The *N*-heteroaryl analogues have potencies greater than that of morphine, with significant differences between 5- and 8-quinolyl isomers (2,3) indicating that the heterocyclic conforma-

Correspondence to: E. F. Llama, Departamento de Química Orgánica y Farmacéutica, F. Farmacia, Universidad Complutense, 28040 Madrid, Spain.

Table 1. Structure, characterization and properties of fentanyl analogues.

| Compound<br>(Fentanyl) | Heterocycle                       | R <sub>1</sub>                | R <sub>2</sub>  | m.p. °C | Elemental analysis<br>(theoretical) |             |               | EC <sub>50</sub><br>(mg kg <sup>-1</sup> ) |
|------------------------|-----------------------------------|-------------------------------|---|---------|-------------------------------------|-------------|---------------|--|
|                        |                                   |                               |   |         | C                                   | H           | N             |  |
| A 1                    | C <sub>6</sub> H <sub>5</sub>     | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> |         |                                     |             |               | 0.03                                       |
| 2                      | 5-Quinolyl                        | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 183-184 | 77.31 (77.48)                       | 7.76 (7.54) | 10.63 (10.84) | 0.19                                       |
| 3                      | 8-Quinolyl                        | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 202-203 | 77.51 (77.48)                       | 7.48 (7.54) | 10.91 (10.84) | 1.96                                       |
| 4                      | 5-Isoquinolyl                     | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 176     | 77.62 (77.48)                       | 7.42 (7.54) | 11.01 (10.84) | 0.65                                       |
| 5                      | 9-Acridinyl                       | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 212-213 | 79.45 (79.60)                       | 7.32 (7.14) | 9.42 (9.60)   | 1.42                                       |
| 6                      | 7-Benzo(b) (1,8)<br>phenanthrolyl | C <sub>2</sub> H <sub>5</sub> | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 260     | 78.78 (78.65)                       | 6.51 (6.60) | 11.52 (11.46) | > 2.5                                      |
| B 7                    | 5-Quinolyl                        | C <sub>2</sub> H <sub>5</sub> | CH <sub>3</sub>   | 146-147 | 72.80 (72.69)                       | 7.60 (7.79) | 14.30 (14.12) | > 2.5                                      |
| 8                      | 8-Quinolyl                        | C <sub>2</sub> H <sub>5</sub> | CH <sub>3</sub>   | 158-159 | 72.49 (72.69)                       | 7.83 (7.79) | 14.02 (14.12) | > 2.5                                      |
| 9                      | 5-Acridinyl                       | CH <sub>3</sub>               | CH <sub>3</sub>   | 166-167 | 76.28 (76.04)                       | 7.11 (7.25) | 12.21 (12.09) | > 2.5                                      |
| C10                    | 5-Quinolyl                        | CH <sub>3</sub>               | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 177     | 77.32 (77.17)                       | 7.09 (7.28) | 11.37 (11.25) | 1.45                                       |
| 3                      | 8-Quinolyl                        | CH <sub>3</sub>               | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 186     | 77.22 (77.17)                       | 7.17 (7.28) | 11.30 (11.25) | 2.35                                       |
| 4                      | 5-Isoquinolyl                     | CH <sub>3</sub>               | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 169-170 | 77.04 (77.17)                       | 7.35 (7.28) | 11.10 (11.25) | 1.85                                       |
| 5                      | 9-Acridinyl                       | CH <sub>3</sub>               | (CH <sub>2</sub> ) <sub>6</sub> C <sub>6</sub> H <sub>5</sub> | 195     | 79.59 (79.40)                       | 6.79 (6.90) | 10.02 (9.92)  | > 2.5                                      |
| Morphine               |                                   |                               |   |         |                                     |             |               | 3.15                                       |

tion has relevance for the opiate-receptor interaction. The structural rigidity of these compounds compared with fentanyl may explain the lack of activity as attempts to restrict the conformational flexibility of fentanyl have been shown to lead to decreased activity (Berger et al 1977; Borne et al 1984; Fifer et al 1984).

Replacement of *N*-propionyl by *N*-acetyl in the active compounds 2-5 depressed the potency. However, in these compounds (Series C, 10-12) the antinociceptive activity at 2.5 mg kg<sup>-1</sup> lower doses was maintained which is surprising because the *N*-propionyl group in fentanyl and its derivatives seems to be essential for the opiate-receptor interaction (Lobezoo et al 1980; Lobezoo & Soudijn 1981). The explanation may lie in a substantial increase of opiate receptor affinity for the heteroaromatic ring region or a capacity of the opiate receptor to bind structurally different morphinomimetics in different orientations.

Lack of activity up to at least 2.5 mg kg<sup>-1</sup> on *N*-methyl substitution of the piperidine ring was observed (Series B) indicating that the *N*-phenylethyl group is necessary for the interaction with opiate receptor(s). This is in agreement with the report of Fifer et al (1984). None of the compounds exhibited antagonism to fentanyl-induced effects in rats at doses of 2.5 mg kg<sup>-1</sup>. Finally, the property of several of these derivatives in sharing antinociceptive activity indicates that substitution with a heteroaromatic ring and the lack of an *N*-propionyl group does not lead to a complete loss of antinociceptive activity in this series of opioids.

#### References

- Atwell, G. J., Cain, B. F., Baguley, B. C., Finlay, G. J., Denny, W. A. (1984) Potential antitumor agents. Synthesis and biological activity of dibasic-9-aminoacridine-4-carboxamides. *J. Med. Chem.* 27: 1481-1485
- Bagley, J. R., Wynn, R. L., Rudo, F. G., Doorley, B. M., Spencer,

H. K. (1989) New 4-(heteroanilido) piperidines, structurally related to the pure opioid agonist fentanyl with agonist and/or antagonist properties. *Ibid.* 32: 663-671

Berger, J. G., Davidson, F., Langford, G. E. (1977) Synthesis of some conformationally restricted analogues of fentanyl. *Ibid.* 20: 600-602

Borne, R. F., Fifer, E. K., Waters, I. W. (1984) Conformationally restrained fentanyl analogues. 2. Synthesis and analgetic evaluation of perhydro-1,6-naphthyridin-2-ones. *Ibid.* 27: 1271-1275

Butler, J. L., Gordon, M. (1975) A reinvestigation of known bromination reactions of quinoline. *J. Heterocyclic Chem.* 12: 1015-1020

Casy, A. F., Huckstep, M. R. (1988) Structure-activity studies of fentanyl. *J. Pharm. Pharmacol.* 40: 605-608

Casy, A. F., Parfitt, R. T. (1986) Opioid Analgesics: Chemistry and Receptors. Plenum Press, London and New York, pp 287-301

Elslager, E. F., Tendick, F. H. (1962) Synthetic amebicides: benzo[b][1-8]phenanthrolines. *J. Med. Pharm. Chem.* 5: 546-558

Fifer, E. K., Davis, W. M., Borne, R. F. (1984) Fentanyl analogues 3. 2-(1,2,3,4-Tetrahydro)-naphthyl substituted 4-anilidopiperidines. *Eur. J. Med. Chem.* 19: 519-524

Gordon, M., Pearson, D. E. (1964) The swamping catalyst the halogenation of isoquinoline and quinoline. *J. Org. Chem.* 29: 329-332

Harper, N. J., Chignell, C. F. (1964) The chemistry and pharmacology of some 4-aminopiperidines and their derivatives. *J. Med. Chem.* 7: 729-732

Janssen, P. A. J., Niemegeers, C. J. E., Dony, J. C. H. (1963) The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail-withdrawal reflex in rats. *Arzneim. Forsch.* 13: 502-506

Lobezoo, M. W., Soudijn, W. (1981) Opiate receptor interaction of compounds derived from and structurally related to fentanyl. *J. Med. Chem.* 24: 777-782

Lobezoo, M. W., Soudijn, W., Wijngaarden, I. (1980) Structure and receptor interactions of morphinomimetics Part I. Hydroxy and methoxy derivatives of fentanyl and some morphine analogues. *Eur. J. Med. Chem.* 15: 357-361